Alnylam Pharma (ALNY) Misses Q3 EPS by 42c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Alnylam Pharma (ALNY) Misses Q3 EPS by 42c

Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity

November 7, 2018 8:00 AM EST

Obtained FDA and EMA Approvals of ONPATTRO (patisiran) the First-Ever RNAi Therapeutic and Launched in U.S. and EU

Received 125 U.S. Patient Start Forms in First Seven Weeks of ONPATTRO Launch

Reported Positive Topline Interim Analysis Results from ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyrias

Advanced Lumasiran into ILLUMINATE Phase 3 Program

Maintained Strong Balance Sheet with $1.27 Billion in Cash and Expects to End 2018 with Approximately $1.0 Billion in Cash

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More